Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Altman

Showing results (321-330 of 365) with videos related to

Pageof 37
Sort By:
Blood|August 2, 2022
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapyEunice S Wang, Pau Montesinos, Mark D Minden, et al.
The Lancet. Oncology|June 4, 2018
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trialJorge Cortes, Alexander E Perl, Hartmut Döhner, et al.
Blood|May 5, 2018
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, et al.
Blood Advances|August 8, 2020
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adultsMikkael A Sekeres, Gordon Guyatt, Gregory Abel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Chronic Myelogenous Leukemia, Version 1.2014Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
Blood Advances|September 8, 2022
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentationHarry J Iland, Nigel Russell, Richard Dillon, et al.
JAMA Oncology|February 27, 2025
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 TrialAnand P Jillella, Sandra J Lee, Jessica K Altman, et al.
Blood Advances|October 30, 2023
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 studyJessica K Altman, Tsila Zuckerman, Jamie Koprivnikar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Chronic myelogenous leukemia, version 1.2015Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
Blood|January 21, 2022
Structural racism is a mediator of disparities in acute myeloid leukemia outcomesIvy Elizabeth Abraham, Garth H Rauscher, Anand Ashwin Patel, et al.
Pageof 37

Showing results (321-330 of 365) with videos related to

Sort By:
Pageof 37
Blood|August 2, 2022
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapyEunice S Wang, Pau Montesinos, Mark D Minden, et al.
The Lancet. Oncology|June 4, 2018
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trialJorge Cortes, Alexander E Perl, Hartmut Döhner, et al.
Blood|May 5, 2018
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, et al.
Blood Advances|August 8, 2020
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adultsMikkael A Sekeres, Gordon Guyatt, Gregory Abel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Chronic Myelogenous Leukemia, Version 1.2014Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
Blood Advances|September 8, 2022
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentationHarry J Iland, Nigel Russell, Richard Dillon, et al.
JAMA Oncology|February 27, 2025
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 TrialAnand P Jillella, Sandra J Lee, Jessica K Altman, et al.
Blood Advances|October 30, 2023
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 studyJessica K Altman, Tsila Zuckerman, Jamie Koprivnikar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Chronic myelogenous leukemia, version 1.2015Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
Blood|January 21, 2022
Structural racism is a mediator of disparities in acute myeloid leukemia outcomesIvy Elizabeth Abraham, Garth H Rauscher, Anand Ashwin Patel, et al.
Pageof 37